Alluvi, previously BI 4744, represents a notable development in obesity treatment. This dual stimulator targeting both glucagon-like peptide-1 and GIP targets demonstrates remarkable effectiveness in patient studies, https://worldsocialindex.com/story7239012/alluvi-a-detailed-investigation-into-retatrutide-s-potential